vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPAMT CORP（PAMT）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $141.3M、PAMT CORPの約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -20.7%、差は34.0%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -15.1%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-25.0M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -12.0%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
AMPH vs PAMT — 直接比較
売上が大きい
AMPH
1.3倍大きい
$141.3M
売上成長率が高い
AMPH
+13.3%の差
-15.1%
純利益率が高い
AMPH
純利益率が34.0%高い
-20.7%
フリーキャッシュフローが多い
AMPH
FCF $49.6M多い
$-25.0M
2年売上CAGRが高い
AMPH
2年複合成長率
-12.0%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $141.3M |
| 純利益 | $24.4M | $-29.3M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | -27.0% |
| 純利益率 | 13.3% | -20.7% |
| 売上前年比 | -1.8% | -15.1% |
| 純利益前年比 | -35.7% | 7.4% |
| EPS（希薄化後） | $0.51 | $-1.38 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上AMPHPAMT
| Q4 25 | $183.1M | $141.3M | ||
| Q3 25 | $191.8M | $150.3M | ||
| Q2 25 | $174.4M | $151.1M | ||
| Q1 25 | $170.5M | $155.3M | ||
| Q4 24 | $186.5M | $166.5M | ||
| Q3 24 | $191.2M | $182.6M | ||
| Q2 24 | $182.4M | $182.9M | ||
| Q1 24 | $171.8M | $182.6M |
純利益AMPHPAMT
| Q4 25 | $24.4M | $-29.3M | ||
| Q3 25 | $17.4M | $-5.6M | ||
| Q2 25 | $31.0M | $-9.6M | ||
| Q1 25 | $25.3M | $-8.1M | ||
| Q4 24 | $38.0M | $-31.6M | ||
| Q3 24 | $40.4M | $2.4M | ||
| Q2 24 | $37.9M | $-2.9M | ||
| Q1 24 | $43.2M | $281.0K |
粗利率AMPHPAMT
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
営業利益率AMPHPAMT
| Q4 25 | 19.4% | -27.0% | ||
| Q3 25 | 13.2% | -3.8% | ||
| Q2 25 | 24.2% | -7.3% | ||
| Q1 25 | 21.9% | -5.9% | ||
| Q4 24 | 24.2% | -22.6% | ||
| Q3 24 | 29.8% | 1.3% | ||
| Q2 24 | 30.3% | -0.4% | ||
| Q1 24 | 27.9% | -0.4% |
純利益率AMPHPAMT
| Q4 25 | 13.3% | -20.7% | ||
| Q3 25 | 9.0% | -3.7% | ||
| Q2 25 | 17.8% | -6.4% | ||
| Q1 25 | 14.8% | -5.2% | ||
| Q4 24 | 20.4% | -19.0% | ||
| Q3 24 | 21.1% | 1.3% | ||
| Q2 24 | 20.8% | -1.6% | ||
| Q1 24 | 25.1% | 0.2% |
EPS（希薄化後）AMPHPAMT
| Q4 25 | $0.51 | $-1.38 | ||
| Q3 25 | $0.37 | $-0.27 | ||
| Q2 25 | $0.64 | $-0.46 | ||
| Q1 25 | $0.51 | $-0.37 | ||
| Q4 24 | $0.74 | $-1.44 | ||
| Q3 24 | $0.78 | $0.11 | ||
| Q2 24 | $0.73 | $-0.13 | ||
| Q1 24 | $0.81 | $0.01 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $83.7M |
| 総負債低いほど良い | $608.7M | $333.9M |
| 株主資本純資産 | $788.8M | $210.5M |
| 総資産 | $1.6B | $697.9M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 1.59× |
8四半期トレンド — 暦四半期で整列
現金・短期投資AMPHPAMT
| Q4 25 | $282.8M | $83.7M | ||
| Q3 25 | $276.2M | $115.6M | ||
| Q2 25 | $231.8M | $117.3M | ||
| Q1 25 | $236.9M | $102.7M | ||
| Q4 24 | $221.6M | $110.7M | ||
| Q3 24 | $250.5M | $92.3M | ||
| Q2 24 | $217.8M | $114.0M | ||
| Q1 24 | $289.6M | $125.8M |
総負債AMPHPAMT
| Q4 25 | $608.7M | $333.9M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $325.6M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
株主資本AMPHPAMT
| Q4 25 | $788.8M | $210.5M | ||
| Q3 25 | $776.7M | $239.5M | ||
| Q2 25 | $757.5M | $244.9M | ||
| Q1 25 | $751.3M | $269.6M | ||
| Q4 24 | $732.3M | $277.5M | ||
| Q3 24 | $727.7M | $308.9M | ||
| Q2 24 | $713.3M | $306.7M | ||
| Q1 24 | $672.4M | $314.6M |
総資産AMPHPAMT
| Q4 25 | $1.6B | $697.9M | ||
| Q3 25 | $1.7B | $715.2M | ||
| Q2 25 | $1.6B | $707.9M | ||
| Q1 25 | $1.6B | $712.6M | ||
| Q4 24 | $1.6B | $741.7M | ||
| Q3 24 | $1.5B | $756.7M | ||
| Q2 24 | $1.5B | $733.5M | ||
| Q1 24 | $1.6B | $746.4M |
負債/資本比率AMPHPAMT
| Q4 25 | 0.77× | 1.59× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.17× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-5.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-25.0M |
| FCFマージンFCF / 売上 | 13.4% | -17.7% |
| 設備投資強度設備投資 / 売上 | 4.5% | 13.6% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-23.4M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローAMPHPAMT
| Q4 25 | $32.9M | $-5.8M | ||
| Q3 25 | $52.6M | $5.9M | ||
| Q2 25 | $35.6M | $12.2M | ||
| Q1 25 | $35.1M | $5.0M | ||
| Q4 24 | $29.0M | $15.2M | ||
| Q3 24 | $60.0M | $15.5M | ||
| Q2 24 | $69.1M | $18.7M | ||
| Q1 24 | $55.3M | $9.6M |
フリーキャッシュフローAMPHPAMT
| Q4 25 | $24.6M | $-25.0M | ||
| Q3 25 | $47.2M | $2.5M | ||
| Q2 25 | $25.0M | $5.9M | ||
| Q1 25 | $24.4M | $-6.8M | ||
| Q4 24 | $16.6M | $-39.9M | ||
| Q3 24 | $46.2M | $-33.6M | ||
| Q2 24 | $63.1M | $4.1M | ||
| Q1 24 | $46.5M | $-12.2M |
FCFマージンAMPHPAMT
| Q4 25 | 13.4% | -17.7% | ||
| Q3 25 | 24.6% | 1.7% | ||
| Q2 25 | 14.3% | 3.9% | ||
| Q1 25 | 14.3% | -4.4% | ||
| Q4 24 | 8.9% | -24.0% | ||
| Q3 24 | 24.1% | -18.4% | ||
| Q2 24 | 34.6% | 2.2% | ||
| Q1 24 | 27.1% | -6.7% |
設備投資強度AMPHPAMT
| Q4 25 | 4.5% | 13.6% | ||
| Q3 25 | 2.8% | 2.3% | ||
| Q2 25 | 6.1% | 4.2% | ||
| Q1 25 | 6.3% | 7.6% | ||
| Q4 24 | 6.7% | 33.1% | ||
| Q3 24 | 7.2% | 26.9% | ||
| Q2 24 | 3.3% | 8.0% | ||
| Q1 24 | 5.1% | 12.0% |
キャッシュ転換率AMPHPAMT
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 6.44× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 34.11× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
